PFG Advisors Acquires 1,899 Shares of Gilead Sciences, Inc. $GILD

PFG Advisors lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 48.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,844 shares of the biopharmaceutical company’s stock after buying an additional 1,899 shares during the quarter. PFG Advisors’ holdings in Gilead Sciences were worth $648,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of GILD. Pinnacle Wealth Management Advisory Group LLC increased its stake in shares of Gilead Sciences by 1.5% during the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 34,881 shares of the biopharmaceutical company’s stock valued at $3,867,000 after purchasing an additional 506 shares in the last quarter. Future Fund LLC grew its stake in shares of Gilead Sciences by 19.3% in the 2nd quarter. Future Fund LLC now owns 6,578 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 1,063 shares during the last quarter. Midwest Trust Co bought a new position in Gilead Sciences during the 2nd quarter valued at approximately $994,000. DJE Kapital AG raised its stake in Gilead Sciences by 121.7% during the second quarter. DJE Kapital AG now owns 140,881 shares of the biopharmaceutical company’s stock valued at $15,461,000 after buying an additional 77,335 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Gilead Sciences by 94.2% in the second quarter. Acadian Asset Management LLC now owns 767,854 shares of the biopharmaceutical company’s stock worth $85,121,000 after acquiring an additional 372,374 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares in the company, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 71,500 shares of company stock worth $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Argus increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. BMO Capital Markets lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.27.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $122.56 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The firm has a fifty day moving average price of $116.79 and a 200-day moving average price of $112.48. The stock has a market cap of $152.07 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm earned $2.02 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.